AbbVie invests $223m in Singapore manufacturing site

Betsy Goodfellow | January 26, 2024 | News story | Manufacturing and Production |  AbbVie, Pharmacy, Singapore, manufacturing 

AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing facility. This will create more than 100 new jobs and increase the company’s biologics manufacturing capacity.

The facility is located in Singapore’s Tuas Biomedical Park and is a state-of-the-art small-molecule and biologics manufacturing site. The investment is intended to add 24,000 liters of biologic drug-substance to the company’s global manufacturing network, and support current products alongside emerging immunology and oncology compounds in its pipeline.

With this new investment, the company has now invested more than $740m in acquiring, modernising and expanding the Singapore facility over the last decade.

Azita Saleki-Gerhardt PhD, executive vice president and chief operations officer at AbbVie, commented: “This expansion announcement represents one of AbbVie’s many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore. The expansion of our Singapore site will strengthen our global manufacturing capabilities, support our growing biologics pipeline and help AbbVie continue delivering on our patient commitments now and in the future.”

Betsy Goodfellow